Modeling antiretroviral drug responses for HIV-1 infected patients using differential equation models

Advanced Drug Delivery Reviews

Volumn 65, Issue 7, 2013, Pages 940-953

  Xiao, Yanni ^a   Miao, Hongyu ^b   Tang, Sanyi ^c   Wu, Hulin ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c SHAANXI NORMAL UNIVERSITY   (China)

Author keywords

Antiretroviral treatment; HIV AIDS; Inverse problem for ODE; STI; Viral dynamics

Indexed keywords

ANTIRETROVIRAL DRUGS; ANTIRETROVIRAL TREATMENT; DIFFERENT TREATMENTS; DIFFERENTIAL EQUATION MODEL; DISEASE PROGRESSION; HIV/AIDS; PARAMETER ESTIMATION METHOD; STI;

DIFFERENTIAL EQUATIONS; DRUG THERAPY; DYNAMICS; INVERSE PROBLEMS; MATHEMATICAL MODELS; VIRUSES;

DISEASES;

ABACAVIR; ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; DISEASE COURSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG RESPONSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LONG TERM CARE; MATHEMATICAL MODEL; MEDICATION COMPLIANCE; NONPARAMETRIC TEST; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; VIRUS REPLICATION;

ALGORITHMS; ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; TREATMENT OUTCOME;

EID: 84879554697     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.04.005     Document Type: Review

References (159)

1. Aarons L. Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br. J. Clin. Pharmacol. British 2005, 60:581-583.
2. Adams B.M., Banks H.T., Kwon H.D., Tran H.T. Dynamic multidrug therapies for HIV: optimal and STI control approaches. Math. Biosci. Eng. 2004, 1:223-241.
3. Akaike H. Information theory and an extension of the maximum likelihood principle. Second International Symposium on Information Theory. Budapest: Akadémiai Kiadó 1973, 267-281. B. Petrov, F. Csáki (Eds.).
4. Ananworanich J., Gayet-Agernon A., Le Braz M., et al. CD4-guided scheduled treatment interruption compared to continuous therapy: results of the Staccato trial. Lancet 2006, 368:459-465.
5. Althaus C.L., De Boer R.J. Dynamics of immune escape during HIV/SIV infection. PLoS Comput. Biol. 2008, 4(7):e1000103. 10.1371/journal.pcbi.1000103.
6. Arnaout R., Nowak M., Wodarz D. HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing. Proc. R. Soc. Lond. B 2000, 265:1347-1354.
7. Bacaer N. Approximation of the basic reproduction number R0 for vector borne diseases with a periodic vector population. Bull. Math. Biol. 2007, 69:1067-1091.
8. Bainov D.D., Simeonov P.S. Impulsive Differential Equations: Asymptotic Properties of the Solutions 1995, World Scientific, Singapore.
9. Bainov D.D., Simeonov P.S. Impulsive Differential Equations: Periodic Solutions and Applications 1993, Longman Scientific and Technical, Burnt Mill.
10. Bangsberg D.R., Perry S., Charlebois E.D., Clark R.A., Roberston M., Zolopa A.R., Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001, 15:1181-1183.
11. Benson M. Parameter fitting in dynamic model. Ecol. Mod. 1979, 6:97-115.
12. Bernardo M.D., Budd C.J., Champneys A.R., et al. Bifurcations in nonsmooth dynamical systems. SIAM Rev. 2008, 50:629-701.
13. Breban R., Blower S. Role of parametric resonance in virological failure during HIV treatment interruption therapy. Lancet 2006, 367:1285-1289.
14. Blower S.M., Aschenbach A.N., Gershengorn H.B., Kahn J.O. Predicting the unpredictable: transmission of drug-resistant HIV. Nat. Med. 2001, 7:1016-1020.
15. Bonhoeffer S., Nowak M.A. Pre-existence and emergence of drug resistance in HIV-1 infection. Proc. R. Soc. Lond. B 1997, 264:631-637.
16. Bueno L., de Alwis D.P., Pitou C., Yingling J., Lahn M., Glatt S., Trocóniz I.F. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-[beta] kinase antagonist, in mice. Eur. J. Cancer 2008, 44:142-150.
17. Butler S., Kirschner D., Lenhart S. Optimal control of the chemotherapy affecting the infectivity of HIV. Advances in Mathematical Population Dynamics-Molecules, Cells and Man 1997, 557-569. Word Scientific Press, Singapore. O. Arino, D. Axelrod, M. Kimmel (Eds.).
18. Burnham K.P., Anderson D.R. Multimodel inference: understanding AIC and BIC in model selection. Sociol. Methods Res. 2004, 33:261-304.
19. Castro K.G., Ward J.W., Slutsker L., Buehler J.W., Jaffe H.W., Berkelman R.L. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm. Rep. 1993, 41:1-19.
20. Chen J., Wu H. Efficient local estimation for time-varying coefficients in deterministic dynamic models with applications for HIV-1 dynamics. J. Am. Stat. Assoc. 2008, 103:369-384.
21. Chen J., Wu H. Estimation of time-varying parameters in deterministic dynamic models. Stat. Sin. 2008, 18:987-1006.
22. Commenges D., Rondeau V. Relationship between derivatives of the observed and full log likelihoods and application to Newton-Raphson algorithm. Int. J. Biostat. 2006, 2:1-26.
23. Collier A.C., Coombs R.W., Schoenfeld D.A., Bassett R.L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V.J., Friedman H.M., Merigan T.C., Reichman R.C., Hooper C., Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med. 1996, 334:1011-1017.
24. Le Corfec E., Tuckwell H.C. Variability in early HIV-1 population dynamics. AIDS 1998, 12:960-962.
25. Culshaw R.V., Ruan S. A delay-differential equation model of HIV infection of CD4+ T-cells. Math. Biosci. 2000, 165:27-39.
26. Culshaw R.V., Ruan S., Spiteri R.J. Optimal HIV treatment by maximising immune response. J. Math. Biol. 2004, 48:545-562.
27. Dantzig G.B., Thapa M.N. Linear Programming 1: Introduction 1997, Springer-Verlag.
28. Davidian M., Giltinan D.M. Nonlinear Models for Repeated Measurement Data 1995, Chapman and Hall, London.
29. De Boer R.J., Perelson A.S. Towards a general function describing T cell proliferation. J. Theor. Biol. 1995, 175:567-576.
30. De Boer R.J., Perelson A.S. Target cell limited and immune control models of HIV infection: a comparison. J. Theor. Biol. 1998, 190:201-214.
31. De Boer R. Understanding the failure of CD8+ T-cell vaccination against simian/human immunodeficiency virus. J. Virol. 2007, 81:2838-2848.
32. De Leenheer P., Smith H.L. Virus dynamics: a global analysis. SIAM J. Appl. Math. 2003, 63:1313-1327.
33. Deeks S.G., et al. Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days. J. Infect. Dis. 1997, 176:514-517.
34. Deeks S.G. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003, 362:2002-2011.
35. Delyon B., Lavielle M., Moulines E. Convergence of a stochastic approximation version of the EM algorithm. Ann. Stat. 1999, 27:94-128.
36. El-Sadr W.M., Lundgren J.D., Neaton J.D., et al. CD4-T count-guided interruption of antiretroviral treatment, the strategies for management of antiretroviral therapy (SMART) study group. N. Engl. J. Med. 2006, 355:2283-2296.
37. Ellner S.P., Bailey B.A., Bobashev G.V., Gallant A.R., Grenfell B.T., Nychka D.W. Noise and nonlinearity in measles epidemics: combining mechanistic and statistical approaches to population modeling. Am. Nat. 1998, 151:425-440.
38. Fang Y., Wu H., Zhu L. A two-stage estimation method for random coefficient differential equation models with application to longitudinal HIV dynamic data. Stat. Sin. 2011, 21:1145-1170.
39. Feil B., Abonyi J., Pach P., Nemeth S., Arva P., Nemeth M., Nagy G., Rutkowski L., Siekmann J., Tadeusiewicz R., Zadeh L. Semi-mechanistic models for state-estimation - soft sensor for polymer melt index prediction. Artificial Intelligence and Soft Computing-ICAISC 2004, 3070:1111-1117. Springer Berlin/Heidelberg.
40. Ferguson N.M., Donnelly C.A., Hooper J., Ghani A.C., Fraser C., Bartley L.M., Rode R.A., Vernazza P., Lapins D., Mayer S.L., Anderson R.M. Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients. J. Roy. Soc. Interface 2005, 2:349-363.
41. Filippov A.F. Differential Equations with Discontinuous Righthand Sides 1988, Kluwer Academic, Dordrecht.
42. Fister K.R., Lenhart S., McNally J.S. Optimizing chemotherapy in an HIV model. Electr. J. Diff. Equat. 1998, 32:1-12.
43. Friedland G.H., Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999, 13(Suppl. 1):61-72.
44. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications 2000, Apotekarsocieteten, Stockholm.
45. Gill P.E., Murray W., Saunders M.A. An SQP algorithm for large-scale constrained optimization. SIAM Rev. 2005, 47:99-131.
46. Glover F. Heuristics for integer programming using surrogate constraints. Decis. Sci. 1977, 8:156-166.
47. Guedj J., Thiébaut R., Commenges D. Maximum likelihood estimation in dynamical models of HIV. Biometrics 2007, 63:1198-1206.
48. Gupta P., Friberg L.E., Karlsson M.O., Krishnaswami S., French J. A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. J. Clin. Pharmacol. 2010, 50:679-687.
49. Hadjiandreou M.M., Conejeros R., Wilson I. HIV treatment planning on a case-by-case basis. Int. J. Biol. Life Sci. 2011, 7:148-157.
50. Haeno H., Iwasa Y. Probability of resistance evolution for exponentially growing virus in the host. J. Theor. Biol. 2007, 246:323-331.
51. Han C., Chaloner K., Perelson A.S., Gatsoiquiry C., Kass R.E., Carriquiry A., Gelman A., Higdon D., Pauler D.K., Verdinellinis I. Bayesian analysis of a population HIV dynamic model. Case Studies in Bayesian Statistics 2002, 223-237. Springer-Verlag, New York.
52. Harrigan P.R., Whaley M., Montaner J.S. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999, 13:59-62.
53. Heckman N.E., Ramsay J.O. Penalized regression with model-based penalties. Can. J. Stat. 2000, 28:241-258.
54. Heffernan J.M., Wahl L.M. Treatment interruptions and resistance: a review. Deterministic and Stochastic Models of AIDS and HIV with Intervention 2005, 423-456. World Scientific, Singapore. W.Y. Tan, H. Wu (Eds.).
55. Heffernan J.M., Wahl L.M. Monte Carlo estimates of natural variation in HIV infection. J. Theor. Biol. 2005, 236:137-153.
56. Herz A.V., Bonhoeffer S., Anderson R.M., May R.M., Nowak M.A. Viral dynamics in vivo: limitations on estimations on intracellular delay and virus decay. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:7247-7251.
57. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
58. Huang Y., Rosenkranz S.L., Wu H. Modeling HIV dynamics and antiviral responses with consideration of time-varying drug exposures, sensitivities and adherence. Math. Biosci. 2003, 184:165-186.
59. Huang Y., Liu D., Wu H. Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system. Biometrics 2006, 62:413-423.
60. Huang Y., Lu T. Modeling long-term longitudinal HIV dynamics with application to an AIDS clinical study. Ann. Appl. Stat. 2008, 2:1384-1408.
61. Jackson R.C. A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity. J. Pharmacokinet. Pharmacodyn. 1997, 25:713-730.
62. Joshi H.R. Optimal control of an HIV immunology model. Optim. Control. Appl. Math. 2002, 23:199-213.
63. Kajiwara T., Sasaki T. A note on the stability analysis of pathogen-immune interaction dynamics. Discret. Contin. Dyn. Syst. Ser. B 2004, 4:615-622.
64. Kamina A., Makuch R.W., Zhao H. A stochastic modeling of early HIV-1 population dynamics. Math. Biosci. 2001, 170:187-198.
65. Kavli T., Lines G.T. A unifying framework for mechanistic, fuzzy and data driven modeling. EUFIT'96. Aachen, Germany 1996, 1241-1246.
66. Kennedy J., Eberhart R. Particle swarm optimization. Proceedings of IEEE International Conference on Neural Networks 1995, IV:1942-1948.
67. Kesteren C.V., Zandvliet A.S., Karlsson M.O., Mathôt R.A.A., Punt C.J.A., Armand J.P., Raymond E., Huitema A.D.R., Dittrich C., Dumez H., Roché H.H., Droz J.P., Ravic M., Yule S.M., Wanders J., Beijnen J.H., Fumoleau P., Schellens J.H.M. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest. New Drugs 2005, 23:225-234.
68. Kirschner D., Lenhart S., Serbin S. Optimal control of the chemotherapy of HIV. J. Math. Biol. 1997, 35:775-792.
69. Kirschner D.E., Webb G.F. Understanding drug resistance for monotherapy treatment of HIV infection. Bull. Math. Biol. 1997, 59:763-786.
70. Kuhn E., Lavielle M. Coupling a stochastic approximation version of EM with an MCMC procedure. ESAIM Probab. Stat. 2004, 8:115-131.
71. Kuhn E., Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput. Stat. Data Anal. 2005, 49:1020-1038.
72. Labbe L., Verotta D. A nonlinear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients. J. Pharmacokinet. Pharmacodyn. 2006, 33:519-542.
73. Li L., Brown M.B., Lee K.H., Gupta S. Estimation and inference for a spline-enhanced population pharmacokinetic model. Biometrics 2002, 58:601-611.
74. Li M.Y., Shu H. Global dynamics of an in-host viral model with intracellular delay. Bull. Math. Biol. 2010, 72:1492-1505.
75. Liang H., Miao H., Wu H. Estimation of constant and time-varying dynamic parameters of HIV infection in a nonlinear differential equation model. Ann. Appl. Stat. 2010, 4:460-483.
76. Liang H., Wu H. Parameter estimation for differential equation models using a framework of measurement error in regression model. J. Am. Stat. Assoc. 2008, 103:1570-1583.
77. Liu W. Nonlinear oscillation in models of immune response to persistent viruses. Theor. Popul. Biol. 1997, 52:224-230.
78. Louis T.A. Finding the observed information matrix when using the EM algorithm. J. R. Stat. Soc. Ser. B Methodol. 1982, 44:226-233.
79. Maggioloa F., Airoldia M., Callegaro A., et al. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS 2009, 23:799-807.
80. McLean A.R., Nowak M.A. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS 1992, 6:71-79.
81. Merrill S. Modeling the interaction of HIV with the cells of the immune system. Mathematical and Statistical Approaches to AIDS Epidemiology, Lecture Notes in Biomath 1989, Springer-Verlag, New York.
82. Meza C., Jaffrézic F., Foulley J.L. REML estimation of variance parameters in nonlinear mixed effects models using the SAEM algorithm. Biom. J. 2007, 49:876-888.
83. Meza C., Jaffrézic F., Foulley J.L. Estimation in the probit normal model for binary outcomes using the SAEM algorithm. Comput. Stat. Data Anal. 2009, 53:1350-1360.
84. Miao H. Understanding B cell kinetics in human via heavy water labeling using nonlinear mixed effects models and stochastic approximation EM algorithms 2010, Department of Biostatistics & Computational Biology, University of Rochester, (M.S. Thesis).
85. Miao H., Xia X., Perelson A.S., Wu H. On identifiability of nonlinear ODE models and applications in viral dynamics. SIAM Rev. 2011, 53:3-39.
86. Miron R.E., Smith R.J. Modelling imperfect adherence to HIV induction therapy. BMC Infect. Dis. 2010, 10:1-16.
87. Mittler J., Sulzer B., Neumann A., Perelson A.S. Influence of delayed virus production on viral dynamics in HIV-1 infected patients. Math. Biosci. 1998, 152:143-163.
88. Mittler J., Markowitz M., Ho D., Perelson A.S. Refined estimates for HIV-1 clearance rate and intracellular delay. AIDS 1999, 13:1415-1417.
89. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P.J., Mo H.M., Markowitz M., Chernyavskiy T., Niu P., Lyons N., Hsu A., Granneman G.R., Ho D.D., Boucher C.A.B., Leonard J.M., Norbeck D.W., Kempf D.J. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 1996, 2:760-766.
90. Montaner J.S., Harris M., Mo T., Harrigan P.R. Rebound of plasma HIV viral load following prolonged suppression with combination therapy. AIDS 1998, 12:1398-1399.
91. Nelson P.W., Perelson A.S. Mathematical analysis of delay differential equation models of HIV-1 infection. Math. Biosci. 2002, 179:73-94.
92. Nelson P.W., Mittler J., Perelson A.S. Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV-1 viral dynamic parameters. J. Acquir. Immune Defic. Syndr. 2001, 26:405-412.
93. Nelson P.W., Murray J.D., Perelson A.S. A model of HIV-1 pathogenesis that includes an intracellular delay. Math. Biosci. 2000, 163:201-215.
94. Nocedal J., Wright S.J. Numerical Optimization 1999, Springer Verlag, New York.
95. Nowak M.A., May R.M. Virus Dynamics: Mathematical Principles of Immunology and Virology 2000, Oxford University Press, Oxford.
96. Nowak M.A. Variability of HIV infections. J. Theor. Biol. 1992, 155:1-20.
97. Nowak M.A., Anderson R.M., Boerlijst M.C., Bonhoeffer S., May R.M., McMichael A.J. HIV-1 evolution and disease progression. Science 1996, 274:1008-1010.
98. Nowak M.A., Bonhoeffer S., Shaw G.M., May R.M. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J. Theor. Biol. 1997, 184:205-219.
99. Nowak M.A., May R.M. Mathematical biology of HIV infections: antigenic variation and diversity threshold. Math. Biosci. 1991, 106:1-21.
100. Nowak M.A., Bangham C.R.M. Population dynamics of immune responses to persistent viruses. Science 1996, 272:74-79.
101. Nowak M.A., May R.M., Phillips R., Rowland-Jones S., Lalloo D., et al. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995, 375:606-611.
102. O'Brien T.R., et al. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998, 18:155-161.
103. Paterson D.L., Swindells S., Mohr J., Brester M., Vergis E.N., Squler C., Wagener M.M., Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. J. Intern. Med. 2000, 133:21-30.
104. Pearson J.E., Krapivsky A.S. Perelson Stochastic theory of early viral infection: continuous versus burst production of virions. PLoS Comput. Biol. 2011, 7(2):e1001058. 10.1371/journal.
105. Perelson A.S., Nelson P.W. Modeling viral infections. Am. Math. Soc. 2002, 59:139-172.
106. Perelson A.S. Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2002, 2:28-36.
107. Perelson A.S., Nelson P.W. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev. 1999, 41:3-44.
108. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
109. Perelson A.S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., Markowitz M., Ho D.D. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
110. Perelson A.S., Kirschner D.E., de Boer R. Dynamics of HIV infection of CD4+ T cells. Math. Biosci. 1993, 114:81-125.
111. Phillips A.N., Youle M., Johnson M., Loveday C. Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS 2001, 15:2211-2220.
112. Poyton A.A., Varziri M.S., McAuley K.B., McLellen P.J., Ramsay J.O. Parameter estimation in continuous-time dynamic models using principal differential analysis. Comput. Chem. Eng. 2006, 30:698-708.
113. Raboud J.M., et al. Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J. Infect. Dis. 1996, 174:191-194.
114. Ramsay J.O. Principal differential analysis: data reduction by differential operators. J. R. Stat. Soc. Ser. B Methodol. 1996, 58:495-508.
115. Ramsay J.O., Hooker G., Campbell D., Cao J. Parameter estimation for differential equations: a generalized smoothing approach. J. R. Stat. Soc. Ser. B 2007, 69:741-796.
116. Ribeiro R.M., Bonhoeffer S., Nowak M.A. The frequency of resistant mutant virus before antiviral therapy. AIDS 1998, 12:461-465.
117. Ribeiro R.M., Bonhoeffer S. Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:7681-7686.
118. Rodriguez-Fernandez M., Mendes P., Banga J.R. A hybrid approach for efficient and robust parameter estimation in biochemical pathways. Biosystems 2006, 83:248-265.
119. Rong L., Perelson A.S. Modeling HIV persistence, the latent reservoir, and viral blips. J. Theor. Biol. 2009, 260:308-331.
120. Rong L., Feng Z., Perelson A.S. Emergence of HIV-1 drug resistance during antiretroviral treatment. Bull. Math. Biol. 2007, 69:2027-2060.
121. Rosenberg E.S., Davidian M., Banksc H.T. Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection. Drug Alcohol Depend. 2007, 88:41-51.
122. Runge C. Über empirische Funktionen und die Interpolation zwischen äquidistanten Ordinaten. Zeitschrift für Mathematik und Physik. 1901, 46:224-243.
123. Sabin C.A., et al. Course of viral load throughout HIV-1 infection. J. Acquir. Immune Defic. Syndr. 2000, 23:172-177.
124. Samson A., Lavielle M., Mentré F. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Comput. Stat. Data Anal. 2006, 51:1562-1574.
125. Schwarz G. Estimating the dimension of a model. Ann. Stat. 1978, 6:461-464.
126. Seber G.A.F., Wild C.J. Nonlinear Regression 2003, John Wiley & Sons, Inc., Hoboken, New Jersey.
127. Sethi A.K., Celentano D.D., Gange S.J., Moore R.D., Gallant J.E. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin. Infect. Dis. 2003, 37:1112-1118.
128. Sheiner L.B. Modeling pharmacodynamics: parametric and nonparametric approaches. Variability in Drug Therapy: Description, Estimation, and Control 1985, 139-152. Raven Press, New York. M. Rowland, L.B. Sheiner, J.L. Steimer (Eds.).
129. Shiri T., Garira W., Musekwa S.D. A two-strain HIV-1 mathematical model to assess the effects of chemotherapy on disease parameters. Math. Biosci. Eng. 2005, 2:811-832.
130. Smith H.L. Monotone Dynamical Systems 1995, AMS, Providence, RI.
131. Smith R.J., Wahl L.M. Distinct effects of protease and reverse transcriptase inhibitors in an immunological model of HIV-1 infection with impulsive drug effects. Bull. Math. Biol. 2004, 66:1259-1283.
132. Smith R.J., Wahl L.M. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects. Bull. Math. Biol. 2005, 67:783-813.
133. Smith R.J. Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?. Proc. R. Soc. B 2006, 273:617-624.
134. Smith R.J., Aggarwala B.D. Can the viral reservoir of latently infected CD4+ T cells be eradicated with antiretroviral drugs?. J. Math. Biol. 2009, 697-715.
135. Storn R., Price K. Differential evolution-a simple and efficient heuristic for global optimization over continuous spaces. J. Glob. Optim. 1997, 11:341-359.
136. Swartz J., Bremermann H. Discussion of parameter estimation in biological modeling: algorithms for estimation and evaluation of the estimates. J. Math. Biol. 1975, 1:241-275.
137. Tan W.Y., Wu H. Stochastic modeling of the dynamics of CD4+ T-cell infection by HIV and some Monte Carlo studies. Math. Biosci. 1998, 147:173-205.
138. Tang S.Y., Xiao Y.N. One-compartment model with Michaelis-Menten elimination kinetics and therapeutic window: an analytical approach. J. Pharmacokinet. Pharmacodyn. 2007, 34:807-827.
139. Tang S.Y., Xiao Y.N., Wang N., Wu H. Piecewise HIV virus dynamic model with CD4 T cell count-guided therapy. J. Theor. Biol. 2012, 308:123-134.
140. Tuckwell H.C., Le Corfec E. A stochastic model for early HIV-1 population dynamics. J. Theor. Biol. 1998, 195:451-463.
141. Tuckwell H.C., Shipman P.D., Perelson A.S. The probability of HIV infection in a new host and its reduction with microbicides. Math. Biosci. 2008, 214:81-86.
142. Varah J.M. A spline least squares method for numerical parameter estimation in differential equations. SIAM J. Sci. Comput. 1982, 3:28-46.
143. Varziri M.S., McAuley K.B., McLellen P.J. Selecting optimal weighting factors in iPDA for parameter estimation in continuous-time dynamic models. Comput. Chem. Eng. 2008, 32:3011-3022.
144. Wahl L.M., Nowak M.A. Adherence and drug resistance: predictions for therapy outcome. Proc. R. Soc. Lond. B 2000, 267:835-843.
145. Wang Y. Semiparametric mixed-effects analysis on PK/PD models using differential equations. Statistics 2007, University of Nebraska, Lincoln, Nebraska.
146. Wang K., Wang W., Liu X. Global stability in a viral infection model with lytic and nonlytic immune response. Comput. Math. Appl. 2006, 51:1593-1610.
147. Wang Y., Zhou Y., Wu J., Heffernan J. Oscillatory viral dynamics in a delayed HIV pathogenesis model. Math. Biosci. 2009, 219:104-112.
148. Wang W.D., Zhao X.Q. Threshold dynamics for compartmental epidemic models in periodic environments. J. Dyn. Diff. Equat. 2008, 20:699-717.
149. Wei X., et al. Viral dynamics in human immune deficiency virus type 1 infection. Nature 1995, 373:117-122.
150. Wein L.M., Zenios S.A., Nowak M.A. Dynamic multidrug therapies for HIV: a control theoretic approach. J. Theor. Biol. 1997, 185:15-29.
151. Wodarz D., Lloyd A.L. Immune responses and the emergence of drug-resistant virus strains in vivo. Proc. R. Soc. Lond. B 2004, 271:1101-1109.
152. Wolinsky S., Korber B.T., Neumann A.U., Daniels M., Kunstman K.J., Whetsell A.J., Furtado M.R., Cao Y., Ho D.D., Safrit J.T. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996, 272:537-542.
153. Wu H., Huang Y., Acosta E.P., Park J.G., Song Y., Rosenkranz S.L., Kuritzkes D.R., Eron J.J., Perelson A.S., Gerber J.G. Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J. Pharmacokinet. Pharmacodyn. 2006, 33:399-419.
154. Wu H., Ding A.A. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 1999, 55:410-418.
155. Wu H., Huang Y., Acosta E.P., Rosenkranz S.L., Kuritzkes D.R., Eron J.J., Perelson A.S., Gerber J.G. Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence and drug resistance. J. Acquir. Immune Defic. Syndr. 2005, 39:272-283.
156. Ye Y. Interior algorithms for linear, quadratic and linearly constrained non-linear programming 1987, Department of ESS, Stanford University.
157. Yang Y.P., Xiao Y.N. Threshold dynamics for an HIV model in periodic environments. J. Math. Anal. Appl. 2010, 361:59-68.
158. Yang Y.P., Xiao Y.N., Wang N., Wu J.H. Optimal control of drug therapy: melding pharmacokinetics with viral dynamics. Biosystems 2012, 107:174-185.
159. Zhu H., Zou X. Impact of delays in cell infection and virus production on HIV-1 dynamics. IMA J. Math. Med. Biol. 2008, 25:99-112.